Business
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
- Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders - - Advancements demonstrate the ability to specifically integrate correct copies of complete genes, potentially enabling treatment of any disease caused by a loss-of-function mutation - EMERYVILLE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company c
About this update from Metagenomi Therapeutics, Inc.
[{"type":"image","alt":"Metagenomi, Inc.","displaySize":"","headline":null,"caption":"Metagenomi, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":120,"url":"https://media.zenfs.com/en/globenewswire.com/f9f4f8ce15a62dc256eccc8b2b88fc5f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ld3K1HIDljOFxzdNkgn1rg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f9f4f8ce15a62dc256eccc8b2b88fc5f","width":300,"height":120}},"lazy":false},{"type":"text","content":"- Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders -","length":190,"tagName":"p"},{"type":"text","content":"- Advancements demonstrate the ability to specifically integrate correct copies of complete genes, potentially enabling treatment of any disease caused by a loss-of-function mutation -","length":184,"tagName":"p"},{"type":"text","content":"EMERYVILLE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the presentation of three abstracts at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place from May 13 – 17, 2025, in New Orleans, Louisiana. The data showcase Metagenomi’s advancements in compact nucleases for extrahepatic gene editing and CAST (CRISPR-associated transposases) for site-specific integration of large therapeutic genes - underscoring the platform’s potential to drive next-generation, in vivo precision medicines.","length":710,"tagName":"p"},{"type":"text","content":"“Our metagenomics discovery platform is designed to systematically identify and optimize novel gene editing systems by harnessing both natural microbial evolution and AI-guided protein optimization,” said Brian C. Thomas, Ph.D., CEO and founder of Metagenomi. “At ASGCT, we shared early proof-of-concept data across different gene editing technologies - including compact Type II and Type V nucleases for efficient in vivo editing and a programmable Type V-K CAST system capable of targeted integration of large DNA cargoes. While compact nucleases have the potential to improve delivery to har...